These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Determination of adverse reactions of chronic drug therapy as examplified with the hepatotoxic action of isoniazid and rifampicin]. Bartmann K Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1518-29. PubMed ID: 347784 [No Abstract] [Full Text] [Related]
43. [Halothane and antituberculous drugs--a hepatotoxic combination? (author's transl)]. Schmidt-Wilcke HA; Wolfert W; Grundmann E Z Gastroenterol; 1977 Aug; 15(8):504-11. PubMed ID: 906600 [TBL] [Abstract][Full Text] [Related]
45. Medical grand rounds from Touro Infirmary. Mycobacterium kansasii, aortic stenosis and antimicrobial related hepatitis. J La State Med Soc; 1975 Jun; 127(6):227-33. PubMed ID: 1151130 [No Abstract] [Full Text] [Related]
46. Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Askgaard DS; Wilcke T; Døssing M Thorax; 1995 Feb; 50(2):213-4. PubMed ID: 7701468 [TBL] [Abstract][Full Text] [Related]
48. [Fulminant hepatitis in patients with mixed connective tissue disease under antitubercular treatment with hydrazide and rifampicin]. Waitzberg VR; Gayotto LC Rev Hosp Clin Fac Med Sao Paulo; 1982 Feb; 37(1):48-51. PubMed ID: 7123064 [No Abstract] [Full Text] [Related]
49. [Liver damage following antituberculous therapy]. Thaler H Dtsch Med Wochenschr; 1982 Jan; 107(3):113. PubMed ID: 7056159 [No Abstract] [Full Text] [Related]
50. Present views on isoniazid and isoniazid-rifampicin hepatitis. Pessayre D Agressologie; 1982 Jan; 23(A):13-5. PubMed ID: 7081577 [No Abstract] [Full Text] [Related]
51. [A case of acute hepatitis occurred during treatment with isoniazid and rifampicin (author's transl)]. Kameda K; Kawabata S; Shirai S Kekkaku; 1980 May; 55(5):247-51. PubMed ID: 7412075 [No Abstract] [Full Text] [Related]
52. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Pessayre D; Bentata M; Degott C; Nouel O; Miguet JP; Rueff B; Benhamou JP Gastroenterology; 1977 Feb; 72(2):284-9. PubMed ID: 830577 [TBL] [Abstract][Full Text] [Related]
53. [Report on 13 cases (including 3 deaths) of liver damage induced by rifampicin (author's transl)]. Tong YY Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1980 Mar; 3(1):35-8. PubMed ID: 7428575 [No Abstract] [Full Text] [Related]
54. [The hepatotoxicity of rifampicin and its modification through "essential" choline phospholipids]. Kuntz HD; Rausch V; Bammel E Med Welt; 1978 Mar; 29(11):452-4. PubMed ID: 651600 [No Abstract] [Full Text] [Related]
55. [Animal experimental studies on the problem of liver damage by antitubercular agents (rifampicin and isoniazide) by means of the galactosamine model]. Leinweber B; Mahrt R Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():300-3. PubMed ID: 1029192 [No Abstract] [Full Text] [Related]
57. [A case of rifampicin-induced acute renal failure and review of 47 cases with liver dysfunction induced by isoniazid and rifampicin (author's transl)]. Sugiyama Y; Kudo S; Kitamura S; Kosaka K Kekkaku; 1981 Jul; 56(7):375-8. PubMed ID: 7328998 [No Abstract] [Full Text] [Related]
58. [Histopathological and histochemical study of the liver during antituberculotic polychemotherapy in children ]. Mihailovici MS Morphol Embryol (Bucur); 1987; 33(3):205-8. PubMed ID: 2958698 [No Abstract] [Full Text] [Related]
59. [Use of a isoniozid-rifompicin drug hepatotoxicity screening technic in tuberculosis therapy]. Viteau JM; Toulet J; Plonteux G; Abiven M; Bonfante N Sem Hop; 1974 Jun; 50(28):1953-9. PubMed ID: 4374748 [No Abstract] [Full Text] [Related]
60. [Reversible acute hepatic failure after treatment with association of isoniazide-rifampicin (author's transl)]. Le Guillou M; L'Henaff F; Boisseau M; Castaing Y; Bourdalle-Badie C Sem Hop; 1981 Jun 18-25; 57(25-28):1199-201. PubMed ID: 6266037 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]